FAM
PCRX icon

Fulcrum Asset Management’s Pacira BioSciences PCRX Stock Holding History

Fulcrum Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35K Buy
+54
New +$1.28K ﹤0.01% 916

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fulcrum Asset Management's PCRX Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 54 shares worth $1.35K. The stake represents ﹤0.01% of the portfolio and ranks #916 among its holdings.

253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Fulcrum Asset Management held 54 shares of Pacira BioSciences worth $1.35K as of Q2 2026.
  • Pacira BioSciences was a new Fulcrum Asset Management position in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #916 holding.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.